Idorsia
Idorsia is a Swiss pharmaceutical research company in Allschwil, near Basel, Switzerland. After Actelion was bought by Johnson & Johnson in 2017, the Actelion founders, Jean-Paul and Martine Clozel, started their new business, located just across the road from the Actelion headquarters. The company expects to be profitable in 2025.[1]
| ISIN | CH0363463438 |
|---|---|
| Industry | pharmaceutical research |
| Founded | 2017 |
| Founder | Jean-Paul Clozel, Martine Clozel |
| Headquarters | Allschwil, Switzerland |
Key people | Jean-Paul Clozel (CEO), Martine Clozel (Chief Scientific Officer), Guy Braunstein (Chief Medical Officer) |
| Products | clazosentan, daridorexant |
| Revenue | 7 million CHF (2021) |
| -122 million CHF (2021) | |
| -105 million CHF (2021) | |
Number of employees | > 1200 (2022) |
| Website | http://www.idorsia.ch |
Products
Table current as of May 2, 2022, listing the drugs that have reached at least phase 3 trials.[2]
| drug | disease, condition, remarks | phase |
|---|---|---|
| Daridorexant | Insomnia First insomnia drug to improve both night-time symptoms and day-time function[3] | Approved in the United States and the EU[1] |
| Clazosentan | cerebral vasospasm | Approved in Japan |
| Lucerastat | Fabry disease | Phase 3 failed; research into other applications continuing |
| Selatogrel | Acute mycardial infarction | Phase 3 |
References
- Business data for Idorsia AG:
- "Idorsia-Medikament Quviviq erhält Zulassung in der EU" [Idorsia drug Quviviq gains approval in the EU] (in German). cash.ch. 2022-05-03. Retrieved 2022-05-03.
- "Idorsia Company Profile" (PDF). Idorsia. Retrieved 2022-05-02.
- "The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia". 2022-02-22. Retrieved 2022-05-02.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.